NEW DELHI, July 8 — For a continent that has long shouldered a disproportionate share of the global disease burden, the story of vaccines is not merely a matter of laboratory milestones—it is a ledger of lives saved and economic potential unlocked. The World Health Organization estimates that vaccines prevent 2-3 million deaths each year worldwide, a statistic that resonates deeply across South and Southeast Asia, where infectious disease outbreaks can still shutter markets and disrupt supply chains overnight.
The mechanism itself is elegantly simple: vaccines stimulate the immune system to produce a protective response without causing the disease. This principle has ancient roots—the practice of variolation was documented in 10th-century China and India, long before modern science gave it a name.
But the modern era began decisively in 1796, when Edward Jenner developed the smallpox vaccine. That single intervention led to the global eradication of smallpox, declared by the WHO in 1980, and remains one of public health’s greatest achievements.
Platforms and Pathways
Today’s vaccine landscape is a mosaic of different technological platforms, each with distinct advantages for different pathogens and populations. Live-attenuated vaccines—such as the measles, mumps, and rubella (MMR) vaccine introduced in 1971—use weakened versions of the virus. Inactivated vaccines, like Jonas Salk’s polio vaccine approved in 1955, use killed pathogens.
Subunit vaccines, including the hepatitis B vaccine approved in 1986, use only specific pieces of the pathogen. Toxoid vaccines target bacterial toxins, as seen in the diphtheria and tetanus vaccines.
The polio vaccine has reduced global cases by over 99% since 1988, with only 6 cases reported in 2021. For India, which was declared polio-free in 2014, this represents a monumental public health victory that required massive logistical coordination across the country’s most remote villages. Then came the mRNA platform.
The COVID-19 vaccines developed by Pfizer-BioNTech and Moderna, authorized in the United States in December 2020, were developed in 11 months after the SARS-CoV-2 genome was sequenced—the fastest vaccine development in history. The Pfizer-BioNTech vaccine received emergency use authorization in the US on December 11, 2020.
For Asian markets watching the pandemic’s economic toll, this speed was not just a scientific curiosity; it was a signal about how quickly biotech could respond to future threats. Adjuvants have long been part of this equation. Aluminum salts, used in vaccines since the 1920s, are added to enhance the immune response.
These are not new technologies, but their refinement continues to matter for vaccine efficacy across diverse populations.
The Development Pipeline
Vaccine development follows a rigorous, staged process that has not fundamentally changed in decades. Preclinical testing is followed by Phase I trials, which assess safety in 20-100 participants. Phase II trials, involving hundreds of participants, examine dosing and efficacy.
Phase III trials, the largest, enroll thousands to confirm efficacy and monitor for rare side effects. Only after these phases can regulatory approval be sought.
This pipeline is expensive and time-consuming, which is why the COVID-19 vaccine breakthrough was so remarkable. It compressed a process that typically takes a decade into less than a year, without skipping safety steps—though with massive global investment and parallel trial phases. For India’s pharmaceutical sector, which is a major supplier of vaccines to the developing world, these development pathways have direct commercial implications.
The country’s vaccine manufacturers have long produced versions of established vaccines—including the hepatitis B vaccine, the MMR vaccine, and polio vaccines—for domestic use and export to Africa, Southeast Asia, and Latin America.
Herd Immunity and the Unvaccinated
A critical concept in vaccine policy is herd immunity, which occurs when a high percentage of the population is vaccinated. This indirectly protects those who cannot be vaccinated—such as immunocompromised individuals—by reducing the spread of the pathogen. In densely populated Asian cities, achieving herd immunity thresholds has been a persistent challenge, particularly where vaccine hesitancy or supply constraints exist.
The economic stakes are clear. Outbreaks of vaccine-preventable diseases can shut down factories, disrupt agricultural labor, and strain healthcare systems that are already underfunded.
Analysts note that consistent vaccination coverage is one of the highest-return investments a developing economy can make. Louis Pasteur’s development of the rabies vaccine in 1885, using attenuated pathogens, laid the groundwork for the live-attenuated vaccines that followed. That lineage—from Pasteur to the MMR vaccine to today’s mRNA platforms—represents a continuous thread of innovation that has transformed global health.
For investors and policymakers watching the vaccine space in Asia, the key takeaway is this: the platforms exist, the pipeline is proven, and the economic case is overwhelming. What remains is the harder work of distribution, public trust, and sustained political will. Consult your doctor for medical advice.
{“@context”: “https://schema.org”, “@type”: “NewsArticle”, “headline”: “Vaccines Train Immune System: A Historical Scientific Overview”, “description”: “NEW DELHI, July 8 — For a continent that has long shouldered a disproportionate share of the global disease burden, the story of vaccines is…”, “datePublished”: “2026-07-08T09:30:00+00:00”, “author”: {“@type”: “Person”, “name”: “Arjun Mehta”}, “publisher”: {“@type”: “Organization”, “name”: “InfoPulse Today”, “url”: “https://newsfeed.infopulsetoday.com/”}}
